Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents.
There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies.
Compared to monoclonal antibodies produced using traditional hybridoma techniques, recombinant antibodies offer advantages, such as high lot-to-lot consistency, animal-free manufacturing, engineering advancement possibilities, and continuous supply. Given the importance, recombinant antibodies are becoming indispensable tools for basic research, diagnostics, and clinical applications.
Download this app note from Sino Biological to learn more about:
The formats, expressions, and applications of these recombinant antibodies:
- Chimeric Antibodies
- Antibody Fragments
- Bispecific Antibodies
- Fc-Fusion Proteins